Intrathecal administration of adeno-associated-viral vectors for gene therapy
US11135313B2 · kind B2 · utility
2Cited by
25References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2016 |
| Grant date | Oct 5, 2021 |
| Priority date | — |
| Expiry date | Oct 27, 2036 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition comprising at least one AAV vector formulated for intrathecal delivery to the central nervous system is described. The composition comprises at least one expression cassette which contains sequences encoding an immunoglobulin construct linked to expression control sequences therefor and a pharmaceutically acceptable carrier. The immunoglobulin construct may be an immunoglobulin modified to have decreased or no measurable affinity for neonatal Fc receptor (FcRn).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.